Joint Action Personalised Cancer Medicine
Joint Action Personalised Cancer Medicine
Contact person: Stefania Boccia
Short Title: JA PCM
Call for applications: EU4H-2024-PJ-03
Project Code: 101233450
Start date: 01/11/2025
End date: 31/10/2029
Coordinator: Sciensano
Funding body: EUROPEAN UNION
Abstract: Joint Action Personalized cancer medicine (PCM) consists of tailoring cancer treatment to each individual's unique profile, including their medical history, genomics and lifestyle. This approach, which also includes advanced technologies such as sequencing combined with diagnostic imaging, is becoming increasingly important in cancer care, from prevention to end-of-life management. In some cases, it's already a standard part of the practice. Key public health benefits include improved outcomes through personalised care, early prevention and improved survival, all of which contribute to a more effective and sustainable healthcare system across Europe. The aim of this Joint Action (JA) is to make personalised cancer care more accessible and well understood across Europe. The goal is to develop health care strategies that follow individuals throughout their lives, whether they are healthy, battling cancer, or have cancer survivors. The partners of this initiative agree that the best outcomes for patients are achieved by addressing prevention, diagnosis, treatment and follow-up together as part of an integrated approach.
The JA will focus on three main areas:
1. Personalized prevention and early diagnosis
2. Personalized Medicine
3. Personalized follow-up care.
The project builds on successful past projects such as CAN. HEAL and PCM4EU to explore key topics such as cancer prevention pathways, genetic testing, new treatment models, and cutting-edge technologies such as liquid biopsy and remote monitoring. These will be complemented by support activities for training, ethical issues and health technology assessment.
